This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antibiotic Resistance 2013: The Antibiotics Development Pipeline And Strategies To Combat Antibiotic Resistance

Table 3.5 Approved/marketed cephalosporins, which exert their bactericidal effects through the inhibition of cell wall synthesis (Source: Biopharm Reports, 2013).

Table 3.6 Approved/marketed 1st, 2nd, 3rd and 4th generation cephalosporins, which exert their bactericidal effects through the inhibition of cell wall synthesis (Source: Biopharm Reports, 2013).

Table 3.7 Approved/marketed carbapenems and one monobactam (Aztreonam), which exert their bactericidal effects through the inhibition of cell wall synthesis (Source: Biopharm Reports, 2013).

Table 3.8 Approved/marketed aminoglycosides, which exert their bactericidal effects through the inhibition of protein synthesis (Source: Biopharm Reports, 2013).

Table 3.9 Approved/marketed tetracyclines, which exert their bactericidal effects through the inhibition of protein synthesis (Source: Biopharm Reports, 2013).

Table 3.10 Approved/marketed quinolones and fluoroquinolones, which exert their bactericidal effects through the inhibition of DNA transcription (Source: Biopharm Reports, 2013).

Table 3.11 Approved/marketed macrolides, which exert their bactericidal effects through the inhibition of protein synthesis (Source: Biopharm Reports, 2013).

Table 3.12 Approved/marketed combination antibiotics, which exert their bactericidal

effects through the combined effects of both molecules (Source: Biopharm Reports, 2013).

Table 3.13 Approved/marketed folate antagonists, which exert their bactericidal

effects through the inhibition of the folate cycle (Source: Biopharm Reports, 2013).

Table 3.14 Approved/marketed mycobacterials, which exert their mycocidal effects through multiple mechanisms (Source: Biopharm Reports, 2013).

Table 3.15 Approved/marketed glycopeptides, which exert their bactericidal effects through the inhibition cell wall synthesis (Source: Biopharm Reports, 2013).

Table 3.16 Other approved/marketed antibiotics, which exert their bactericidal effects through multiple mechanisms (Source: Biopharm Reports, 2013).

Table 3.17 Other approved/marketed antibiotics, which exert their bactericidal effects through multiple mechanisms (Source: Biopharm Reports, 2013).

Table 4.1 Companies with pipeline bacterial ICorps = blue (Source: Biopharm Reports, 2013)

Table 4.2 Antibiotics in Phase 3 Development (Source: Biopharm Reports, 2013)

Table 4.3 Antibiotics in Phase 2 Development (Source: Biopharm Reports, 2013)

Table 4.4 Antibiotics in Phase 1 Development (Source: Biopharm Reports, 2013)

5 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs